Drug Profile
Research programme: cancer immunotherapeutics - PCI Biotech/Ultimovacs
Latest Information Update: 28 Feb 2020
Price :
$50
*
At a glance
- Originator PCI Biotech; Ultimovacs AS
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer